CN115109582A - Red light-near infrared light LED device and application thereof - Google Patents
Red light-near infrared light LED device and application thereof Download PDFInfo
- Publication number
- CN115109582A CN115109582A CN202210647795.XA CN202210647795A CN115109582A CN 115109582 A CN115109582 A CN 115109582A CN 202210647795 A CN202210647795 A CN 202210647795A CN 115109582 A CN115109582 A CN 115109582A
- Authority
- CN
- China
- Prior art keywords
- near infrared
- red
- led device
- light
- fluorescent powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 claims abstract description 29
- 239000000126 substance Substances 0.000 claims abstract description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000741 silica gel Substances 0.000 claims abstract description 10
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 10
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 7
- 208000001491 myopia Diseases 0.000 claims abstract description 7
- 230000004379 myopia Effects 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 5
- 229910052733 gallium Inorganic materials 0.000 claims abstract description 5
- 229910052738 indium Inorganic materials 0.000 claims abstract description 5
- 229910052706 scandium Inorganic materials 0.000 claims abstract description 5
- 230000000366 juvenile effect Effects 0.000 claims abstract description 4
- 238000012858 packaging process Methods 0.000 claims abstract description 4
- 229910052765 Lutetium Inorganic materials 0.000 claims abstract description 3
- 229910052790 beryllium Inorganic materials 0.000 claims abstract description 3
- 229910052732 germanium Inorganic materials 0.000 claims abstract description 3
- 229910052710 silicon Inorganic materials 0.000 claims abstract description 3
- 238000004806 packaging method and process Methods 0.000 claims abstract 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 23
- 239000002994 raw material Substances 0.000 claims description 18
- 238000001354 calcination Methods 0.000 claims description 15
- 239000004327 boric acid Substances 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 9
- 238000000227 grinding Methods 0.000 claims description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 8
- 229910002651 NO3 Inorganic materials 0.000 claims description 8
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 8
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 8
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 229910052712 strontium Inorganic materials 0.000 claims description 6
- IRPGOXJVTQTAAN-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropanal Chemical compound FC(F)(F)C(F)(F)C=O IRPGOXJVTQTAAN-UHFFFAOYSA-N 0.000 claims description 4
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 claims description 4
- 102100032047 Alsin Human genes 0.000 claims description 4
- 101710187109 Alsin Proteins 0.000 claims description 4
- KLZUFWVZNOTSEM-UHFFFAOYSA-K Aluminum fluoride Inorganic materials F[Al](F)F KLZUFWVZNOTSEM-UHFFFAOYSA-K 0.000 claims description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 4
- OYLGJCQECKOTOL-UHFFFAOYSA-L barium fluoride Chemical compound [F-].[F-].[Ba+2] OYLGJCQECKOTOL-UHFFFAOYSA-L 0.000 claims description 4
- 229910001632 barium fluoride Inorganic materials 0.000 claims description 4
- 125000005619 boric acid group Chemical group 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 238000007872 degassing Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- MIMUSZHMZBJBPO-UHFFFAOYSA-N 6-methoxy-8-nitroquinoline Chemical compound N1=CC=CC2=CC(OC)=CC([N+]([O-])=O)=C21 MIMUSZHMZBJBPO-UHFFFAOYSA-N 0.000 claims description 2
- 235000019270 ammonium chloride Nutrition 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 229940037201 oris Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 208000012902 Nervous system disease Diseases 0.000 abstract description 10
- 208000025966 Neurological disease Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 7
- 239000006041 probiotic Substances 0.000 abstract description 6
- 235000018291 probiotics Nutrition 0.000 abstract description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 230000000529 probiotic effect Effects 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract description 2
- 238000000295 emission spectrum Methods 0.000 description 19
- 238000000695 excitation spectrum Methods 0.000 description 16
- 208000018737 Parkinson disease Diseases 0.000 description 12
- 208000024827 Alzheimer disease Diseases 0.000 description 11
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 241000186660 Lactobacillus Species 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 229940039696 lactobacillus Drugs 0.000 description 8
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 7
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005090 crystal field Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000007149 gut brain axis pathway Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- 229910005191 Ga 2 O 3 Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004002 dopaminergic cell Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/02—Use of particular materials as binders, particle coatings or suspension media therefor
- C09K11/025—Use of particular materials as binders, particle coatings or suspension media therefor non-luminescent particle coatings or suspension media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0622—Optical stimulation for exciting neural tissue
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/77—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals
- C09K11/7708—Vanadates; Chromates; Molybdates; Tungstates
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/77—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals
- C09K11/7728—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals containing europium
- C09K11/77347—Silicon Nitrides or Silicon Oxynitrides
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/77—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals
- C09K11/7728—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals containing europium
- C09K11/77348—Silicon Aluminium Nitrides or Silicon Aluminium Oxynitrides
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L33/00—Semiconductor devices having potential barriers specially adapted for light emission; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof
- H01L33/48—Semiconductor devices having potential barriers specially adapted for light emission; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof characterised by the semiconductor body packages
- H01L33/50—Wavelength conversion elements
- H01L33/501—Wavelength conversion elements characterised by the materials, e.g. binder
- H01L33/502—Wavelength conversion materials
- H01L33/504—Elements with two or more wavelength conversion materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0608—Rectum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0609—Stomach and/or esophagus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
- A61N2005/0663—Coloured light
Landscapes
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Neurosurgery (AREA)
- Power Engineering (AREA)
- Computer Hardware Design (AREA)
- Manufacturing & Machinery (AREA)
- Biophysics (AREA)
- Luminescent Compositions (AREA)
Abstract
The invention belongs to the field of LED device preparation, and discloses a red light-near infrared light LED device and application thereof. The LED device is prepared by mixing red light-near infrared light fluorescent powder, transparent silica gel and optional red light fluorescent powder and packaging by a packaging process; the chemical formula of the red light-near infrared light fluorescent powder is as follows: li (M) 1‑x Cr x )O 2 Wherein M is at least one of Sc, Al, Ga, In, Lu, Be, Mg, Si and Ge, 0<x<0.10. According to the inventionThe red light-near infrared light LED device can be used for treating gastrointestinal diseases, neurological diseases, juvenile myopia and other probiotic supplement related diseases, and can also be used in other occasions requiring red light-near infrared light.
Description
Technical Field
The invention belongs to the field of LED device preparation, and particularly relates to a red light-near infrared light LED device and application thereof.
Background
Since the market popularization of white light LED lighting started in 2011, the application of LEDs in the fields of home and office lighting, photosynthetic agriculture and plant factories, ultraviolet sterilization, industrial curing and the like makes a great breakthrough, new applications need to be developed in the future development of the LED industry, the manufacturing technology of visible light and ultraviolet band LED devices is improved day by day, and one direction with a great development prospect is biomedical science. With the innovation of light source technology, light sources for phototherapy are no longer limited to lasers, and the same effect as lasers can be achieved by using LEDs. In the field of academia, the latest technology for disease treatment by light is called Photobiomodulation (PBM). Both PBM and LLLT (low dose laser therapy) utilize photon or photonic means for disease treatment.
Previous LLLT studies have shown that using a combination of wavelengths works better than using a single wavelength, mainly because the laser used in LLLT is linear light, while the absorption spectrum of biological tissue tends to be broadband. The laser light source is used in phototherapy, and the defects of limited selectable wavelength, narrow coverage wavelength range and the like exist. In addition, laser equipment is complex and expensive. The LED light source utilizing fluorescence conversion is a continuous broadband spectrum, which is beneficial to overcoming the defect of LLLT linear light. Compared with laser, the solid-state LED light source has the remarkable advantages of small size, high reliability, portability, low cost and the like.
Parkinson's Disease (PD) and Alzheimer's Disease (AD) are two common neurodegenerative diseases of the elderly, seriously jeopardizing human life health and reducing quality of life. Typical symptoms of PD patients are unique motor deficits including tremor, rigidity, akinesia, and postural instability, often associated with the loss of dopaminergic cells of the substantia nigra pars compacta. Typical symptoms of AD patients are cognitive deficits, the main pathological features being synapses and neuronal degeneration as well as amyloid plaques and neurofibrillary tangles. In addition, mitochondrial dysfunction appears in PD and AD patients in the early and late stages of the disease. At present, the medical community adopts medicines for treating two diseases, but the method can only relieve the symptoms of patients and cannot prevent or further prevent the neuronal degeneration. Numerous studies have shown that PBM can promote neurons to release dopamine, a neurotransmitter capable of producing a large amount of ATP and increasing mitochondrial activity, and is considered as a final measure capable of fundamentally treating neurodegenerative diseases.
In addition to the typical pathological symptoms described above, another major symptom of PD and AD patients is intestinal dysfunction, often with symptoms of intestinal dysfunction in PD patients that are earlier than their typical motor deficit characteristics. The "brain-gut axis" mechanism is a widely accepted view of the pathogenesis of neurological diseases at present, i.e. the gut nervous system connects the gut to the central nervous system via nervous, hormonal and immunological signals, and the gut microbiome is an important signal source. Thus, one of the current ways to treat neurological disorders is to take probiotics and achieve positive therapeutic effects.
The influence of light on cellular energy metabolism is a commonly recognized action mechanism of PBM, and particularly, light acts on Cytochrome C Oxidase (CCO) in mitochondria to increase the permeability of the mitochondrial membrane, the active oxygen is transiently increased, a mitochondrial signal pathway related to neuroprotection and cell survival is activated, nitric oxide released by photodissociation of CCO and synthesis of CCO can stimulate vasodilation and blood flow, and ATP production is promoted by increasing oxygen consumption.
Light not only affects cellular metabolism, but also can modulate microbial activity. In addition to taking drugs that alleviate typical pathologies, an important strategy for PD, AD treatment is to modulate the patient's intestinal microbial profile according to the "brain-gut axis" mechanism, where lactic acid bacteria, as a typical probiotic, are of great significance for PD, AD treatment. Therefore, the PBM method is adopted to regulate the microorganisms in the brain-intestinal axis, is hopeful to complement the conventional medicine and surgical treatment, and has positive treatment effect on the neurological diseases.
The pathogenesis of myopia is unknown, and the mainstream view is that the elongation of the axis of the axio-myopic eye is controlled by the neurotransmitter dopamine, and secondly is related to fundus and sclera hypoxia. The use of PBMs to stimulate the release of the neurotransmitter dopamine from retinal dopamine neurons and to reduce oxidative stress damage has been demonstrated in our studies. PBM is considered to be the ultimate measure that will eventually overcome the myopia problem in humans.
At present, the blue light LED chip has mature technical process and reliable raw materials, and MOVCD equipment for growing the blue light chip is abundant, but the conversion of the 450-plus 480nm blue light emitted by the LED chip into the 850-nm red light-near infrared light with the peak wavelength of 800-plus is a great challenge due to the huge Stokes shift. Suitable luminescent centers are Cr 3+ 、Eu 2+ However, Eu 2+ The near infrared luminescence is mainly caused by defect luminescence, but the defect thermal stability is poor, so that the method is not suitable for industrial application.
Therefore, it is urgent to provide a new red-near infrared LED device to meet the requirements of non-invasive PBM treatment of neurological diseases and myopia PBM treatment for light sources.
Disclosure of Invention
The invention aims to provide a red light-near infrared light LED device aiming at the defects of the prior art. The red light-near red light LED device can be used for treating gastrointestinal diseases, neurological diseases, juvenile myopia and other probiotic supplement related diseases.
In order to achieve the above object, a first aspect of the present invention provides a red-near infrared LED device, which is prepared by mixing red-near infrared phosphor, transparent silica gel, and optionally red phosphor, and encapsulating the mixture by an encapsulation process;
the chemical formula of the red light-near infrared light fluorescent powder is as follows: li (M) 1-x Cr x )O 2 Wherein M is at least one of Sc, Al, Ga, In, Lu, Be, Mg, Si and Ge, 0<x<0.10。
According to the present invention, preferably, the red-near infrared phosphor has a chemical formula of: li [ A ] 1-x-2z (B z C z )]Cr x O 2 Wherein A is at least one of Sc, Al, Ga, In and Lu, B is Be and/or Mg, C is Si and/or Ge, 0<x<0.10，0<z<0.01。
According to the present invention, it is preferable that the raw material containing the element M is at least one of an oxide, a nitrate, an oxalate, and a carbonate containing the element M.
According to the present invention, preferably, the raw material containing the element a is at least one of an oxide, a nitrate, an oxalate, and a carbonate containing the element a.
According to the present invention, it is preferable that the raw material containing the element B is at least one of an oxide, a nitrate, an oxalate, and a carbonate containing the element B.
According to the present invention, preferably, the raw material containing the element C is at least one of an oxide, a nitrate, an oxalate, and a carbonate containing the element C.
According to the present invention, preferably, the red-near infrared phosphor has a chemical formula of: li (Sc) 1-x-y Ga y )Cr x O 2 Wherein 0 is<y<1。
According to the present invention, preferably, the red-near infrared phosphor has a chemical formula of: li (Sc) 1-x-m Al m )Cr x O 2 Wherein 0 is<m<1。
According to the present invention, preferably, the preparation method of the red-near infrared phosphor comprises:
the first step is as follows: will contain Cr 3+ Grinding and mixing the raw material containing the element M and the fluxing agent uniformly, and carrying out primary calcination, dehydration, degassing and removal of surface adsorbed substances to obtain a first-step product;
the second step is that: and grinding the product obtained in the first step, then carrying out secondary calcination, crushing, grinding, washing, filtering and drying to obtain the red light-near infrared light fluorescent powder.
According to the present invention, preferably, the operating conditions of the first calcination include: heating to 300 ℃ at a speed of 3-10 ℃/min in air, preserving heat for 0.3-2 hours, heating to 1000 ℃ at a speed of 3-10 ℃/min, preserving heat for 1-3 hours, cooling to 350 ℃ at a speed of 250 ℃ at a speed of 5-10 ℃/min, cutting off power, and cooling to 25-30 ℃ with the furnace.
According to the present invention, preferably, the operating conditions of the second calcination include: heating to 900 ℃ at a speed of 3-10 ℃/min in the air, preserving heat for 0.5-1.5 hours, heating to 1100-.
According to the invention, the addition amount of the fluxing agent is preferably 1.5-3.5% of the total mass of the raw materials used for preparing the red-near infrared fluorescent powder.
According to the present invention, preferably, the flux is at least one of aluminum fluoride, barium fluoride, ammonium chloride, ammonium fluoride, ammonium bifluoride, and boric acid, and preferably, the flux is boric acid.
According to the invention, the ratio of the dosage of the red light-near infrared light fluorescent powder to the dosage of the red light fluorescent powder to the dosage of the transparent silica gel is preferably (1-3): 0-0.1): 1.
According to the present invention, the red phosphor has a chemical formula of (Ca, Sr) AlSiN 3 :Eu 2+ Or is Q 2 Si 5 N 8 :Eu 2+ Wherein Q is at least one of Sr, Ca, Ba and Mg.
According to the present invention, preferably, the packaging process includes: and (3) defoaming and degassing a mixture of the red light-near infrared light fluorescent powder, the transparent silica gel and the optional red light fluorescent powder, titrating the mixture on a blue light LED chip, and baking and curing to obtain the red light-near infrared light LED device.
According to the invention, the emission wavelength peak of the blue LED chip is preferably 400-500 nm.
According to the invention, preferably, the emission wavelength range of the red-near infrared light LED device is 700-950nm, and the emission wavelength peak value is 813-835 nm.
The invention provides application of the red light-near infrared light LED device as a light source for treating gastrointestinal diseases, neurological diseases and juvenile myopia. In the invention, the red light-near infrared light LED device is used as a light source manufactured by using the device and medical instruments and equipment manufactured by using the device and a light-emitting device. The application of the invention, including but not limited to medical instruments and equipment, can also be other applications developed by using the near-infrared LED device manufactured by the invention.
The technical scheme of the invention has the following beneficial effects:
(1) the red light-near infrared light fluorescent material used by the invention has a perovskite-like crystal structure, the high-symmetry substrate is beneficial to improving the luminous efficiency, the emission wavelength range is 700-950nm, the emission wavelength peak value is adjustable within 813-835nm, the whole spectrum red shift of the encapsulated LED device is 50-150nm, and the encapsulated LED device has the potential of photobiotherapy application; two excitation bands are arranged at 400-800nm, and can be effectively excited by blue light; the absorptivity and internal and external quantum efficiency of the red light-near infrared light fluorescent material are respectively 40.9%, 34.5% and 14.1%.
(2) Compared with a laser light source, the light source generated by the red light-near infrared light LED device has the remarkable advantages of low cost, portability and the like, particularly, the emission spectrum of the light source is a wide band spectrum and is consistent with the wide band absorption of a light receptor in an organism, and compared with the linear light of the laser light source, the light source is more suitable for PBM.
(3) The red light-near infrared light LED device has the photoelectric conversion efficiency of 7.92% under the drive current of 20 mA.
(4) The red light-near infrared light LED device can be used for medical light sources and equipment, treating gastrointestinal diseases, nervous diseases (stimulating secretion and growth of dopamine and neurons, having important significance for prevention, control and treatment of the nervous diseases and complications such as Parkinson's disease and Alzheimer's disease) and other probiotic supplementation related diseases, and can also be used for other purposes.
(5) The research of using the red light-near infrared light LED device to carry out light irradiation on the lactobacillus to adjust the activity shows positive influence, and further proves the important reference value of the device for adjusting the brain-intestine axis of the nervous diseases.
(6) The light source emitted by the red light-near infrared light fluorescent material can promote the growth of intestinal lactobacillus of the organism, promote the expression of anti-inflammatory factors and promote the balance of intestinal flora in the organism by regulating the activity of cells in the organism, and has prevention, control and treatment effects on preventing and treating nervous diseases such as Parkinson's disease and Alzheimer's disease.
Additional features and advantages of the invention will be set forth in the detailed description which follows.
Drawings
The above and other objects, features and advantages of the present invention will become more apparent by describing in detail exemplary embodiments thereof with reference to the attached drawings, wherein like reference numerals generally represent like parts in the exemplary embodiments of the present invention.
FIG. 1 shows the emission spectra of red-near infrared phosphors provided in examples 1-5 of the present invention.
FIG. 2 shows the excitation spectra of red-NIR phosphors provided in examples 1-5 of the present invention.
FIG. 3 shows the emission spectra of red-NIR phosphors provided in examples 6-9 of the present invention.
FIG. 4 shows the excitation spectra of red-NIR phosphors provided in examples 6-9 of the present invention.
FIG. 5 shows the emission spectra of red-NIR phosphors provided in examples 10-13 of the present invention.
FIG. 6 shows the excitation spectra of red-NIR phosphors provided in examples 10-13 of the present invention.
FIG. 7 shows emission spectra of red-near infrared phosphors provided in examples 14-16 of the present invention.
FIG. 8 shows the excitation spectra of red-NIR phosphors provided in examples 14-16 of the present invention.
FIG. 9 shows the emission spectra of red-near infrared phosphors provided in examples 17-20 of the present invention.
FIG. 10 shows the excitation spectra of red-NIR phosphors provided in examples 17-20 of the present invention.
FIG. 11 shows emission spectra of red-near infrared phosphors provided in examples 21-25 of the present invention.
FIG. 12 shows the excitation spectra of red-NIR phosphors provided in examples 21-25 of the present invention.
FIG. 13 shows the emission spectra of red-NIR phosphors provided in examples 26-30 of the present invention.
FIG. 14 shows the excitation spectra of red-NIR phosphors provided in examples 26-30 of the present invention.
FIG. 15 shows XRD patterns of red-near infrared phosphors provided in examples 26-30 of the present invention.
FIG. 16 shows an emission spectrum of a red-near infrared phosphor provided in example 31 of the present invention.
Fig. 17 shows an excitation spectrum of the red-near infrared phosphor provided in example 31 of the present invention.
Fig. 18 shows emission spectra of a red-near infrared LED device provided in embodiment 32 of the present invention under different direct current driving conditions.
Fig. 19 shows a photoelectric conversion efficiency and a light output power curve of a red-near infrared LED device according to embodiment 32 of the present invention as a function of current.
FIG. 20 is a graph showing the comparison of the red-near infrared LED device of example 32 of the present invention with the DNA synthesis rate, the absorption spectrum of cytochrome C oxidase.
FIGS. 21(a) - (b) show the growth of lactic acid bacteria after 24h culture (no light (a) and 720nm light (b)) in the test examples of the present invention.
Detailed Description
Preferred embodiments of the present invention will be described in more detail below. While the following describes preferred embodiments of the present invention, it should be understood that the present invention may be embodied in various forms and should not be limited by the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
In the following examples, the raw materials used to prepare the red-near infrared phosphor include:
MgO(98.5％)、Sc 2 O 3 (99.99％)、Ga 2 O 3 (99.99％)、Cr 2 O 3 (99.99％)。Li 2 CO 3 (99.99%) and Al 2 O 3 (99.99％)。
Examples 1 to 5
Examples 1-5 provide red-near infrared phosphors having the formula: li (M) 1-x Cr x )O 2 Wherein M is Sc (x ═ 0.06), Al (x ═ 0.06), Ga (x ═ 0.06), In (x ═ 0.06), Lu (x ═ 0.06), respectively.
The preparation method of the red light-near infrared light fluorescent powder comprises the following steps:
the first step is as follows: will contain Cr 3+ Grinding and mixing the raw material containing the element M and the fluxing agent uniformly, and carrying out primary calcination, dehydration, degassing and removal of surface adsorbed substances to obtain a first-step product;
the second step: and grinding the product obtained in the first step, then carrying out secondary calcination, crushing, grinding, washing, filtering and drying to obtain the red light-near infrared light fluorescent powder.
The operating conditions of the first calcination include: heating to 176 ℃ at a speed of 5 ℃/min in the air, preserving heat for 2 hours, heating to 900 ℃ at a speed of 5 ℃/min, preserving heat for 2 hours, cooling to 300 ℃ at a speed of 5 ℃/min, powering off, and cooling to 25 ℃ along with the furnace;
the operating conditions of the second calcination include: heating to 900 deg.C at 5 deg.C/min in air, holding for 1 hr, heating to 1100 deg.C at 5 deg.C/min, holding for 6 hr, cooling to 900 deg.C at 5 deg.C/min, holding for 0.5-2 hr, cooling to 300 deg.C at 5 deg.C/min, cutting off power, and cooling to 25 deg.C with the furnace.
The fluxing agent is boric acid, and the addition amount of the boric acid is 2.5% of the total mass of the raw materials used for preparing the red light-near infrared light fluorescent powder.
The emission spectrum and excitation spectrum of the red-near infrared phosphors of examples 1 to 5 are shown in FIGS. 1 and 2. As is clear from FIGS. 1 and 2, Li (Al) in example 2 0.94 Cr 0.06 )O 2 And Li (Ga) of example 3 0.94 Cr 0.06 )O 2 Due to [ MO ] 4 ]The tetrahedral structure and the excessive difference of the ionic radii can not realize Cr 3+ Thus, the red-near infrared phosphor that gives the best emission is the Li (Sc) of example 1 0.94 Cr 0.06 )O 2 。
Examples 6 to 9
Examples 6 to 9 provide a red-near infrared phosphor Li (Sc) 0.94 Cr 0.06 )O 2 Examples 6-9 differ from example 1 only in that: the second temperature rise in the second calcination operation is different, and is 1200 ℃, 1250 ℃, 1300 ℃ and 1350 ℃.
The emission spectrum and excitation spectrum of the red-near infrared phosphors of examples 6 to 9 are shown in FIGS. 3 and 4. As can be seen from fig. 3 and 4, the optimum temperature for the second temperature increase in the second calcination operation is 1250 ℃.
Examples 10 to 13
Examples 10-13 provide Red-near Infrared phosphor Li (Sc) 0.94 Cr 0.06 )O 2 Examples 10-13 differ from example 7 only in that: the fluxing agent is aluminum fluoride, barium fluoride, ammonium fluoride and boric acid, and the addition amounts of the aluminum fluoride, the barium fluoride, the ammonium fluoride and the boric acid are respectively and independently 2.0 percent of the total mass of the raw materials for preparing the red light-near infrared light fluorescent powder.
The emission spectra and excitation spectra of the red-near infrared phosphors of examples 10-13 are shown in FIGS. 5 and 6. As is clear from FIGS. 5 and 6, the most preferable flux is boric acid of example 13.
Examples 14 to 16
Examples 14 to 16 provide Red-near Infrared phosphor Li (Sc) 0.94 Cr 0.06 )O 2 Examples 14-16 differ from example 13 only in that: adding 2.0% boric acid as fluxing agent, the second timeThe heat preservation time when the temperature is raised to 1250 ℃ for the second time in the calcination operation is different and is respectively 4h, 8h and 10 h.
The emission spectra and excitation spectra of the red-near infrared phosphors of examples 14-16 are shown in FIGS. 7 and 8. As is clear from fig. 7 and 8, the optimum temperature retention time for the second temperature rise in the second firing operation was 8 hours in example 15.
Examples 17 to 20
Examples 17 to 20 provide a red-near infrared phosphor Li (Sc) 0.94 Cr 0.06 )O 2 Examples 17-20 differ from example 15 only in that: the boric acid accounts for 1.5 percent, 2.5 percent, 3 percent and 3.5 percent of the total mass of the raw materials used for preparing the red light-near infrared light fluorescent powder respectively.
The emission spectra and excitation spectra of the red-near infrared phosphors of examples 17-20 are shown in FIGS. 9 and 10. As is clear from fig. 9 and 10, the optimum amount of boric acid added was 2.5% of example 18.
Examples 21 to 25
Examples 21-25 provide red-near infrared phosphors having the formula: li (M) 1-x Cr x )O 2 Wherein M is Sc, x is 0.01, 0.02, 0.03, 0.04 and 0.05 respectively.
The red-near infrared phosphors of examples 21-25 were prepared in the same manner as in example 18.
The emission spectra and excitation spectra of the red-near infrared phosphors of examples 21-25 are shown in FIGS. 11 and 12. As can be seen from FIGS. 11 and 12, the red-near infrared phosphor which gives the best emission was Li (Sc) of example 22 0.98 Cr 0.02 )O 2 。
Examples 26 to 30
Examples 26-30 provide red-near infrared phosphors having the formula: li (Sc) 1-x-y Ga y )Cr x O 2 Wherein: x is 0.02, and y is 0, 0.2, 0.4, 0.6, 0.8, respectively.
The red-near infrared phosphors of examples 26 to 30 were prepared in the same manner as in example 22.
Emission spectra of the red-near infrared phosphors of examples 26 to 30,The excitation spectrum and XRD patterns are shown in FIGS. 13-15, respectively, due to the incorporation of Ga 3+ Cannot substitute Sc 3+ Occupying it in Li (Sc) 0.98 Cr 0.02 )O 2 Sites in the lattice, which are more prone to Li during temperature rise 2 CO 3 Formation of LiGaO 2 Thus doping Ga 3+ To Li (Sc) 0.98 Cr 0.02 )O 2 The lattice will cause a reduction in luminescence.
From examples 1 to 30, it is clear that Li (Sc) varies depending on the temperature rise, the holding time, the kind of flux and the amount of addition 1-x Cr x )O 2 The peak value of the emission wavelength of the fluorescent powder generates micro-movement, the movement range is 830nm-834nm, because the crystal field slightly changes due to different sintering environments, but the crystal field changes with Cr 3+ Increase in doping concentration x, Li (Sc) 1-x Cr x )O 2 The peak value of the emission wavelength of the fluorescent powder is obviously moved, and the peak value of the emission wavelength generates large movement within the range of 813-833nm when the Cr is 3+ When the concentration is reduced to x-0.02, the emission peak emits light most intensely at 820 nm. Emission wavelength and spectrum configuration with Cr 3+ The significant variation in concentration is due to the different concentrations of Cr 3+ Entering the crystal lattice changes the crystal field strength.
Example 31
Example 31 provides a red-near infrared phosphor having the formula:
Li[Sc 0.97 (Mg 0.005 Si 0.005 )]Cr 0.02 O 2
the emission spectrum and excitation spectrum of the red-near infrared phosphor of example 31 are shown in FIGS. 16 and 17.
Example 32
The present embodiment provides a red-near infrared LED device that uses Li (Sc) 0.98 Cr 0.02 )O 2 、(Ca,Sr)AlSiN 3 :Eu 2+ The mixture mixed with the transparent silica gel is defoamed, degassed, titrated on a blue light LED chip with the emission wavelength peak value of 450nm, and baked and cured to obtain the transparent silica gel;
the Li (Sc) 0.98 Cr 0.02 )O 2 Amount of (A) to be used、(Ca,Sr)AlSiN 3 :Eu 2+ The ratio of the dosage of (a) to the dosage of the transparent silica gel is 1.83: 0.05: 1.
the emission spectrum of the LED device and related parameters of the device in this embodiment are shown in fig. 18 and 19, and the device reaches the strongest emission at 843nm at 120mA driving current, at this time, the output power of the device is the maximum and can reach 18.25mW, and when the driving current is 20mA, the photoelectric conversion efficiency can reach 7.92% at the maximum.
Test example 1
This test example compares the red-near infrared LED device of this example 32 with the DNA synthesis rate and the absorption spectrum of cytochrome C oxidase, as shown in fig. 20:
the absorbance peaks of cytochrome C oxidase at 620, 820, 760 and 680nm were Cu A Reduced, oxidized, Cu B Reduced state, oxidized state. The infrared fluorescent powder can cover both (Cu) A Reduced, oxidized, Cu B Reduced state, oxidized state) at 820nm, theoretically, can accelerate electron transfer in the mitochondrial respiratory chain and can alleviate mitochondrial dysfunction in parkinson and alzheimer patients by increasing mitochondrial activity.
Because the genetic material of human cells is DNA, the infrared fluorescent powder and the emitted light can theoretically regulate the growth of various cells of the human body including neuron cells, microglia and the like by regulating and controlling the synthesis rate of the DNA.
Therefore, the red light-near infrared light fluorescent powder and the red light-near infrared light LED device have the potential of photobiotics for treating the neurological diseases. Since PBM has important applications in the treatment of neurodegenerative diseases represented by parkinson's disease and alzheimer's disease, more and more studies are actively advancing the work. Table 1 summarizes experimental models and wavelengths, light doses and efficacy of photobiotherapy for neurological disorders. The data in Table 1 show that near-red light with a peak wavelength of 800-.
TABLE 1
Test example 2
This test example utilized a red-near infrared LED device Li (Sc) 0.98 Cr 0.02 )O 2 Performing light-induced lactobacillus experiment, culturing lactobacillus in 37 deg.C constant temperature incubator in dark place for 24 hr by solid culture method, wherein the concentration of lactobacillus in the solid culture medium is controlled within a range of 30-300cfu/ml, and the lactobacillus in the culture medium receives 20mW/cm per day 2 The light dose and the irradiation density are 1.5J/cm 2 Irradiating in a pulse mode for 3 times a day, wherein each irradiation is 0.5J/cm 2 Colonies in each medium were counted or aligned 2h after the end of the last light exposure. FIGS. 21(a) - (b) are the culture medium after 24h incubation, (a) no light dark incubation, and (b) use of a red-near infrared LED device Li (Sc) 0.98 Cr 0.02 )O 2 In the culture medium subjected to PBM, the lactobacillus irradiated by 820nm can be obviously seen to grow in a sheet connection manner, and cannot be counted because the lactobacillus grows too fast and densely, but the growth promotion effect of the light source is macroscopically verified. The action mechanism of lactic acid bacteria in PD and AD is combined, and the red light-near infrared light LED device Li (Sc) provided by the invention 0.98 Cr 0.02 )O 2 And the emitted light can promote the growth of probiotics represented by lactic acid bacteria, so that the treatment of the neurological diseases is realized.
Having described embodiments of the present invention, the foregoing description is intended to be exemplary, not exhaustive, and not limited to the embodiments disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments.
Claims (10)
1. A red light-near infrared light LED device is characterized in that the LED device is prepared by mixing red light-near infrared light fluorescent powder, transparent silica gel and optional red light fluorescent powder and packaging the mixture by a packaging process;
the chemical formula of the red light-near infrared light fluorescent powder is as follows: li (M) 1-x Cr x )O 2 Wherein M is at least one of Sc, Al, Ga, In, Lu, Be, Mg, Si and Ge, 0<x<0.10。
2. The red-near infrared LED device of claim 1, wherein the red-near infrared phosphor has a chemical formula of: li [ A ] 1-x-2z (B z C z )]Cr x O 2 Wherein A is at least one of Sc, Al, Ga, In and Lu, B is Be and/or Mg, C is Si and/or Ge, 0<x<0.10，0<z<0.01。
3. The red-near infrared LED device of claim 2,
the raw material containing the element M is at least one of oxide, nitrate, oxalate and carbonate containing the element M;
the raw material containing the element A is at least one of oxide, nitrate, oxalate and carbonate containing the element A;
the raw material containing the element B is at least one of oxide, nitrate, oxalate and carbonate containing the element B;
the raw material containing the element C is at least one of oxide, nitrate, oxalate and carbonate containing the element C.
4. The red-near infrared LED device of claim 1, wherein the red-near infrared phosphor has a chemical formula of: li (Sc) 1-x-y Ga y )Cr x O 2 Wherein 0 is<y<1。
5. The red-near infrared LED device of claim 1, wherein the red-near infrared phosphor has a chemical formula of: li (Sc) 1-x-m Al m )Cr x O 2 Wherein 0 is<m<1。
6. The red-near infrared LED device according to claim 1, wherein the method for preparing the red-near infrared phosphor comprises:
the first step is as follows: will contain Cr 3+ Grinding and mixing the raw material containing the element M and the fluxing agent uniformly, and carrying out primary calcination to obtain a product in the first step;
the second step is that: and grinding the product obtained in the first step, then carrying out secondary calcination, crushing, grinding, washing, filtering and drying to obtain the red light-near infrared light fluorescent powder.
7. The red-near infrared LED device of claim 6,
the operating conditions of the first calcination include: heating to 300 ℃ at a speed of 3-10 ℃/min in air, preserving heat for 0.3-2 hours, heating to 1000 ℃ at a speed of 3-10 ℃/min, preserving heat for 1-3 hours, cooling to 350 ℃ at a speed of 250 ℃ at a speed of 5-10 ℃/min, powering off, and cooling to 25-30 ℃ along with the furnace;
the operating conditions of the second calcination include: heating to 900 ℃ at a speed of 3-10 ℃/min in the air, preserving heat for 0.5-1.5 hours, heating to 1100-;
the addition amount of the fluxing agent is 1.5-3.5% of the total mass of the raw materials used for preparing the red light-near infrared light fluorescent powder;
the fluxing agent is at least one of aluminum fluoride, barium fluoride, ammonium chloride, ammonium fluoride, ammonium bifluoride and boric acid, and preferably the fluxing agent is boric acid.
8. The red-near infrared LED device of claim 1,
the ratio of the dosage of the red light-near infrared light fluorescent powder to the dosage of the red light fluorescent powder to the dosage of the transparent silica gel is (1-3) to (0-0.1) to 1;
the chemical formula of the red phosphor is (Ca, Sr) AlSiN 3 :Eu 2+ Or is orIs Q 2 Si 5 N 8 :Eu 2+ Wherein Q is at least one of Sr, Ca, Ba and Mg;
the packaging process comprises the following steps: defoaming and degassing a mixture of red light-near infrared light fluorescent powder, transparent silica gel and optional red light fluorescent powder, then titrating the mixture on a blue light LED chip, and baking and curing the mixture to obtain the red light-near infrared light LED device;
preferably, the peak value of the emission wavelength of the blue LED chip is 400-500 nm.
9. The red-near infrared LED device according to any of claims 1 to 8, wherein the emission wavelength range of the red-near infrared LED device is 700-950nm, and the emission wavelength peak is 813-835 nm.
10. Use of a red-near infrared LED device according to any one of claims 1-9 as a light source for the treatment of gastrointestinal, neurological and juvenile myopia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210647795.XA CN115109582B (en) | 2022-06-09 | 2022-06-09 | Red light-near infrared light LED device and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210647795.XA CN115109582B (en) | 2022-06-09 | 2022-06-09 | Red light-near infrared light LED device and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115109582A true CN115109582A (en) | 2022-09-27 |
| CN115109582B CN115109582B (en) | 2024-08-30 |
Family
ID=83326037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210647795.XA Active CN115109582B (en) | 2022-06-09 | 2022-06-09 | Red light-near infrared light LED device and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115109582B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5080471A (en) * | 1990-04-06 | 1992-01-14 | Eic Laboratories, Inc. | Electrochromic material and electro-optical device using same |
| JPH07268318A (en) * | 1994-03-30 | 1995-10-17 | Toshiba Corp | Fluorescent substance, its production and fluorescent lamp |
| JPH10139444A (en) * | 1996-11-12 | 1998-05-26 | Asahi Chem Ind Co Ltd | Production of lithium composite oxide and non-aqueous secondary battery |
| JP2006045449A (en) * | 2004-08-09 | 2006-02-16 | Konica Minolta Holdings Inc | Vacuum ultraviolet ray excitation fluorophor particle and plasma display (pdp) panel |
| CN1979928A (en) * | 2005-12-09 | 2007-06-13 | 中国科学院物理研究所 | Lithium-contained composite metal oxide material of lamina structure and use thereof |
| WO2021035782A1 (en) * | 2019-08-29 | 2021-03-04 | 合肥工业大学智能制造技术研究院 | Special light source and light fixture suitable for diabetic retinopathy |
| CN113346079A (en) * | 2021-05-11 | 2021-09-03 | 浙江帕瓦新能源股份有限公司 | Scandium phase doping and titanium chromium lithium phosphate modified anode material precursor and preparation method thereof |
| CN113563884A (en) * | 2021-08-30 | 2021-10-29 | 合肥工业大学 | Near-infrared fluorescent material and preparation method thereof, and LED light-emitting device and preparation method thereof |
| CN114507517A (en) * | 2022-03-04 | 2022-05-17 | 浙江大学 | Broadband near-infrared fluorescent powder based on spinel structure and preparation method and application thereof |
-
2022
- 2022-06-09 CN CN202210647795.XA patent/CN115109582B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5080471A (en) * | 1990-04-06 | 1992-01-14 | Eic Laboratories, Inc. | Electrochromic material and electro-optical device using same |
| JPH07268318A (en) * | 1994-03-30 | 1995-10-17 | Toshiba Corp | Fluorescent substance, its production and fluorescent lamp |
| JPH10139444A (en) * | 1996-11-12 | 1998-05-26 | Asahi Chem Ind Co Ltd | Production of lithium composite oxide and non-aqueous secondary battery |
| JP2006045449A (en) * | 2004-08-09 | 2006-02-16 | Konica Minolta Holdings Inc | Vacuum ultraviolet ray excitation fluorophor particle and plasma display (pdp) panel |
| CN1979928A (en) * | 2005-12-09 | 2007-06-13 | 中国科学院物理研究所 | Lithium-contained composite metal oxide material of lamina structure and use thereof |
| WO2021035782A1 (en) * | 2019-08-29 | 2021-03-04 | 合肥工业大学智能制造技术研究院 | Special light source and light fixture suitable for diabetic retinopathy |
| CN113346079A (en) * | 2021-05-11 | 2021-09-03 | 浙江帕瓦新能源股份有限公司 | Scandium phase doping and titanium chromium lithium phosphate modified anode material precursor and preparation method thereof |
| CN113563884A (en) * | 2021-08-30 | 2021-10-29 | 合肥工业大学 | Near-infrared fluorescent material and preparation method thereof, and LED light-emitting device and preparation method thereof |
| CN114507517A (en) * | 2022-03-04 | 2022-05-17 | 浙江大学 | Broadband near-infrared fluorescent powder based on spinel structure and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115109582B (en) | 2024-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2968972B1 (en) | Quantum dot light-emitting diodes for phototherapy | |
| US20190174594A1 (en) | Photonic engine system for actuating the photosynthetic electron transport chain | |
| US3670193A (en) | Electric lamps producing energy in the visible and ultra-violet ranges | |
| US11291164B2 (en) | Light source for plant cultivation | |
| CN109550049A (en) | Application of the carbon quantum dot-class graphite phase carbon nitride catalysis material in preparation sterilization and the drug for promoting skin scar healing | |
| US12048853B2 (en) | Light irradiation apparatus | |
| CN115109582B (en) | Red light-near infrared light LED device and application thereof | |
| CN115224176A (en) | Far-red light LED device and application thereof | |
| Mary et al. | Phytochemical assisted synthesis of Ni doped ZnO nanoparticles using aloe vera extract for enhanced photocatalytic and antibacterial activities. | |
| WO2016115235A1 (en) | System for actuating photosynthetic electron transport chain | |
| CN115132901A (en) | Red light-near infrared light LED device and application thereof | |
| KR101281528B1 (en) | Method for growth promotion of fish using light wavelength | |
| CN113563884B (en) | Near infrared fluorescent material and preparation method thereof, and LED light-emitting device and preparation method thereof | |
| CN113502160B (en) | Blue light excited ultraviolet fluorescent powder and preparation method thereof | |
| EP1375635A1 (en) | Bleaching composition and method of bleaching tooth | |
| JP2022515455A (en) | LED lighting device with additional functions | |
| KR101050504B1 (en) | White light emitting device for the plant cultivation | |
| CN106398688B (en) | A kind of blue light fluorescent powder and its synthetic method treated applied to icterus neonatorum disease in LED component | |
| CN202024186U (en) | LED lamp beneficial to plant growth | |
| CN112704735B (en) | Inorganic ion mediated organic compound nano enzyme, preparation method and application | |
| CN108653730B (en) | Long-afterglow oil sol and preparation method and application thereof | |
| CN117224852A (en) | Phototherapy device for inhibiting neuroinflammation and application | |
| CN111394099B (en) | Preparation and application of novel single-matrix double-light near-infrared tantalum-based pyrochlore material | |
| CN112062474B (en) | Preparation method and application of near-infrared perovskite quantum dot glass | |
| KR102058087B1 (en) | A method for producing nanoparticles using a Dryopteris crassirhizoma extract and nanoparticles prepared therefrom |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |